Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models

BACKGROUND: Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC). However, many patients have to adopt dose reduction or terminate the use of sorafenib because of side effects. In addition, a large number of patients are resistant to sorafenib. Thus, it is esse...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Abin, Cao, Manqing, Guo, Zhigui, Zuo, Bingfeng, Gao, Junrong, Zhou, Hongyuan, Li, Huikai, Cui, Yunlong, Fang, Feng, Zhang, Wei, Song, Tianqiang, Li, Qiang, Zhu, Xiaolin, Yin, Haifang, Sun, Huichuan, Zhang, Ti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784359/
https://www.ncbi.nlm.nih.gov/pubmed/26957312
http://dx.doi.org/10.1186/s13045-016-0253-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784359/
https://www.ncbi.nlm.nih.gov/pubmed/26957312
http://dx.doi.org/10.1186/s13045-016-0253-6

Ejemplares similares